ProCE Banner Activity

My Thoughts Regarding Use of Adjuvant Osimertinib for Early-Stage EGFR Mutation–Positive NSCLC

Clinical Thought
Adjuvant osimertinib has been approved for the treatment of patients with resectable early-stage EGFR-positive NSCLC for 2 years. A lung cancer expert discusses the continued DFS benefit and lack of OS data to date and reviews considerations for using adjuvant osimertinib in the clinic.

Released: October 24, 2022

Expiration: October 23, 2023

No longer available for credit.

Share

Faculty

Edward B. Garon

Edward B. Garon, MD, MS

Professor of Medicine
Director of Thoracic Oncology
David Geffen School of Medicine at UCLA
Los Angeles, California

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Lilly

Faculty Disclosure

Primary Author

Edward B. Garon, MD, MS

Professor of Medicine
Director of Thoracic Oncology
David Geffen School of Medicine at UCLA
Los Angeles, California

Edward B. Garon, MD, MS: consultant: ABL Bio, Boehringer Ingelheim, Bristol-Myers Squibb, Dracen, Eisai, EMD Serono, GlaxoSmithKline, Lilly, Merck, Natera, Novartis, Regeneron, Sanofi, Shionogi, Xilio; researcher: ABL Bio, AstraZeneca, Bristol-Myers Squibb, Dynavax, EMD Serono, Genentech, Iovance, Lilly, Merck, Mirati, Neon, Novartis.